-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 9th, Karyopharm Therapeutics, a partner of Deqi Pharmaceuticals, announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting that eltanexor was used to treat myelodysplastic syndrome (MDS) refractory to demethylation drugs (HMA).
The trial is a phase I/II clinical study aimed at evaluating single-agent eltanexor in the treatment of higher-risk MDS patients, that is, according to the International Prognostic Scoring System (IPSS) assessed as intermediate-risk-2 or high-risk MDS patients, and the proportion of bone marrow blasts It is 5-19%
Among the 20 patients enrolled in the group, 15 patients can be evaluated for efficacy
MDS patients refractory to demethylation drugs have limited treatment options and poor prognosis.
Note: The original text has been deleted